{"id":556702,"date":"2026-06-03T12:30:00","date_gmt":"2026-06-03T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=556702"},"modified":"2026-06-03T13:07:00","modified_gmt":"2026-06-03T11:07:00","slug":"recorrencia-apos-inibicao-da-btk-factores-de-prognostico-e-opcoes-de-tratamento","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/recorrencia-apos-inibicao-da-btk-factores-de-prognostico-e-opcoes-de-tratamento\/","title":{"rendered":"Recorr\u00eancia ap\u00f3s inibi\u00e7\u00e3o da BTK – factores de progn\u00f3stico e op\u00e7\u00f5es de tratamento"},"content":{"rendered":"\n

O linfoma de c\u00e9lulas do manto (LCM) \u00e9 um linfoma n\u00e3o-Hodgkin de c\u00e9lulas B raro com uma evolu\u00e7\u00e3o extremamente heterog\u00e9nea. O espetro varia desde formas indolentes e lentamente progressivas at\u00e9 variantes altamente agressivas. O diagn\u00f3stico e o tratamento continuam a ser um desafio, uma vez que a apresenta\u00e7\u00e3o cl\u00ednica, os marcadores moleculares e a resposta ao tratamento variam muito. Novas terapias direcionadas e projectos de registo internacionais est\u00e3o a melhorar cada vez mais o progn\u00f3stico, embora o LCM continue a ser uma doen\u00e7a complexa. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

O linfoma de c\u00e9lulas do manto (LCM) \u00e9 um linfoma n\u00e3o-Hodgkin de c\u00e9lulas B raro com uma evolu\u00e7\u00e3o extremamente heterog\u00e9nea. O espetro varia desde formas indolentes e lentamente progressivas at\u00e9……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":556703,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Linfoma de c\u00e9lulas mant\u00e9licas","footnotes":""},"category":[11524,11365,11379,11551],"tags":[92789,92773,92791,92793,92782,92778,46286,34648,92786,92785,92797,92790,92798,37090,92796,92795,37097,92792,92781,92772,92787,92780,92769,92788,92784,92775,92770,92771,92779,92776,92794,92774,92777,92783],"powerkit_post_featured":[],"class_list":["post-556702","post","type-post","status-publish","format-standard","has-post-thumbnail","category-formacao-continua","category-hematologia-pt-pt","category-oncologia-pt-pt","category-rx-pt","tag-acalabrutinib","tag-bloqueio-de-bcl2","tag-curso-heterogeneo-mcl","tag-diagnostico-mcl","tag-estado-do-sox11","tag-factores-de-prognostico-do-mcl","tag-histologia","tag-ibrutinib-pt-pt","tag-imunofenotipagem","tag-indice-de-proliferacao-ki-67","tag-inibicao-da-btk","tag-inibidores-da-btk","tag-linfoma-de-celulas-do-manto","tag-linfoma-de-celulas-mantelicas","tag-linfoma-nao-hodgkin-de-celulas-b-2","tag-lmc-indolente","tag-mcl-pt-pt","tag-mcl-agressivo","tag-mutacao-tp53-mcl","tag-pet-ct-mcl","tag-pirtobrutinib","tag-pontuacao-mipi","tag-quimio-imunoterapia-mcl","tag-recidiva-de-mcl","tag-recorrencia-apos-inibicao-da-btk","tag-regime-glove","tag-registo-emcl","tag-sistema-de-tratamento-glove","tag-sobreexpressao-da-ciclina-d1","tag-terapia-com-anticorpos-cd20","tag-terapia-mcl","tag-translocacao-t1114","tag-transplante-autologo-de-celulas-estaminais-mcl","tag-zanubrutinib","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-11 01:22:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":556698,"slug":"recurrencia-tras-la-inhibicion-de-la-btk-factores-pronosticos-y-opciones-de-tratamiento","post_title":"Recurrencia tras la inhibici\u00f3n de la BTK: factores pron\u00f3sticos y opciones de tratamiento","href":"https:\/\/medizinonline.com\/es\/recurrencia-tras-la-inhibicion-de-la-btk-factores-pronosticos-y-opciones-de-tratamiento\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/556702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=556702"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/556702\/revisions"}],"predecessor-version":[{"id":556706,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/556702\/revisions\/556706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/556703"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=556702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=556702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=556702"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=556702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}